Core Viewpoint - The innovative drug sector has experienced fluctuations in the past two months, but significant capital inflows continue through innovative drug-themed ETFs, indicating ongoing investment value in the sector despite recent adjustments [1][2]. Group 1: Market Performance - The innovative drug sector has shown impressive performance this year, with several innovative drug-themed funds doubling in value. However, as of November 27, the average decline in these funds is approximately 10% [2]. - In the fourth quarter, innovative drug-themed ETFs have seen a net subscription amounting to 193.26 billion yuan, with notable contributions from various ETFs, including 36.17 billion yuan from Huatai-PineBridge and 33.2 billion yuan from GF [2]. - The total scale of several innovative drug-themed ETFs has significantly increased this year, with GF's ETF growing from 7.875 billion yuan to 25.505 billion yuan, and Huatai-PineBridge's ETF from 650 million yuan to 24.209 billion yuan [2]. Group 2: Fund Company Movements - Recent movements from fund companies indicate an increased focus on innovative drug-themed products, with multiple ETFs being reported since November 21, including those from GF and Yongan [3]. Group 3: Investment Focus - The innovative drug sector's adjustment is attributed to a mismatch between high-frequency market expectations and the actual pace of industry developments, leading to a need for selective stock picking in the future [4]. - Industry experts suggest that the phase of broad increases in the innovative drug sector may be over, and the next two years will likely see significant differentiation among companies, emphasizing those that have reached breakeven and are expected to sustain high growth in revenue and profits [4]. - The rise of the innovative drug industry in China reflects the country's advantages in talent, cost, and efficiency, with substantial growth potential for quality companies in the international market over the next three years [4][5].

■机构动向 从基金公司最新动向看，近期也在加大创新药主题产品的布局力度。11月21日以来，广发上证科创板创 新药ETF、银华上证科创板创新药ETF、鹏华上证科创板创新药ETF、永赢上证科创板创新药指数基 金、东财中证沪港深创新药产业ETF联接基金等密集上报。 投资要聚焦长期 资金涌入创新药板块 机构专注优质个股挖掘 ◎记者 赵明超 近两个月，创新药板块趋于震荡。但从资金层面看，大量资金还在借道创新药主题ETF入市，进入四季 度，创新药主题ETF合计净申购额近200亿元。多位基金经理表示，创新药板块配置价值依然存在，但 要聚焦行业发展精选个股，布局优质企业。 资金涌入创新药板块 从今年以来的市场表现看，创新药板块整体表现抢眼，多只创新药主题基金净值一度实现翻倍。但进入 四季度，创新药板块遭遇调整，截至11月27日，创新药主题基金平均跌幅约10%。 值得注意的是，在创新药板块的调整行情中，大量资金逆势借道ETF加仓。据Choice测算，四季度以 来，截至11月27日，创新药主题ETF净申购额合计为193.26亿元。其中，汇添富港股通创新药ETF净申 购额为36.17亿元，广发港股创新药ETF为33.2亿元，银华创 ...

Group 1 - The innovation drug sector is experiencing a volatile trend in the fourth quarter, with positive signals in the funding landscape as significant capital flows into innovation drug-themed ETFs, totaling over 19 billion yuan in net subscriptions as of November 28 [1] - Despite a strong performance earlier in the year, the innovation drug sector faced a correction in the fourth quarter, with an average decline of approximately 10% in themed funds as of November 28, yet funds continued to increase their positions, leading to substantial growth in several innovation drug-themed ETFs [3] - The growth of specific ETFs is notable, with the scale of the GF Hong Kong Innovation Drug ETF increasing from 7.875 billion yuan at the end of last year to 25.276 billion yuan, and the Huatai-PineBridge Hong Kong Innovation Drug ETF rising from less than 700 million yuan to over 24 billion yuan [3] Group 2 - Industry experts believe that the long-term investment value of the innovation drug sector is becoming more apparent, although the phase of broad market gains may be over, necessitating a focus on stock selection for future investments [4] - The report from Industrial Securities indicates that the trend of "innovation + internationalization" in the innovation drug industry remains unchanged, with increased elasticity in the sector following the recent adjustments, and a positive outlook on the fundamentals of the innovation drug industry chain [4]

在今年二、三季度经历强势上涨后，近两个月来创新药板块走势逐渐趋于震荡。尽管如此，资金面上却呈现出积极信号——大量资金正借道创新药主题 ETF涌入市场。数据显示，四季度以来，该类ETF合计净申购规模已超过190亿元。 据Choice测算，四季度以来，截至11月28日，创新药主题ETF净申购额超过190亿元。其中，广发港股创新药ETF净申购额为33.27亿元，汇添富港股通创 新药ETF净申购额超过30亿元，银华创新药ETF、广发创新药ETF净申购额也均超过24亿元。 拉长期限来看，今年以来多只创新药主题ETF的规模实现大幅增长。其中，从去年底至今年11月28日，广发港股创新药ETF规模从78.75亿元增至252.76亿 元。类似的还有，汇添富港股通创新药ETF去年底规模不足7亿元，最新规模已超过240亿元。 汇添富港股通创新药ETF的份额变化 从基金公司最新动向看，近期也在加大创新药主题产品的布局力度。 据Choice资讯，11月21日以来，广发上证科创板创新药ETF、银华上证科创板创新药ETF、鹏华上证科创板创新药ETF、永赢上证科创板创新药指数基 金、东财中证沪港深创新药产业ETF联接基金等密集上报。 创新药 ...

Group 1: Performance of ETFs - The innovative drug sector showed strong performance on November 12, with multiple related ETFs rising over 2.5% [1][4] - Defensive ETFs, including financial, consumer, large-cap value, and dividend ETFs, also exhibited significant gains [1][7] - The S&P Biotechnology ETF (159502) and NASDAQ Biotechnology ETF (513290) had notable increases, reflecting the positive trend in the overseas pharmaceutical market [4] Group 2: Fund Flows - The Huaan Gold ETF attracted over 1.4 billion yuan in net inflows over two trading days, driven by rising gold prices [3][9] - Consumer and AI-themed ETFs also saw substantial capital inflows, with several products like the Invesco Hang Seng Consumer ETF and Huatai-PineBridge CSI Major Consumer ETF leading in net inflows [9][10] - The financial sector ETFs, including the non-bank financial ETF, also reported significant net inflows, indicating a shift in investor interest [10] Group 3: Industry Insights - The innovative drug sector is expected to continue its growth trajectory, with a reported revenue increase of 1.98% and a net profit growth of 7.25% year-on-year for the third quarter [11] - The CXO sector showed even stronger performance, with revenue growth of 11.18% and net profit growth of 46.46% [11] - The overall outlook for the innovative drug industry remains positive, supported by domestic policy and a favorable global environment for drug development [11]

Core Insights - The innovative drug-themed ETFs have performed well this year, with many funds achieving positive returns and a significant increase in overall scale, surpassing 100 billion yuan as of November 7 [1][2] Performance Overview - As of now, all 27 innovative drug-themed ETFs have realized net value growth this year, with 9 funds showing a net value growth rate exceeding 50%, and several products maintaining growth rates above 80% [1] - Notable funds include Wanji Zhongzheng Hong Kong Stock Connect Innovative Drug ETF, GF Zhongzheng Hong Kong Innovative Drug ETF, and Yinhua Guozheng Hong Kong Stock Connect Innovative Drug ETF [1] Fund Size and Rankings - Three products have surpassed 10 billion yuan in scale, with GF Hong Kong Innovative Drug ETF leading at 24.636 billion yuan, followed by Huitianfu Hong Kong Stock Connect Innovative Drug ETF at 21.719 billion yuan, and Yinhua Innovative Drug ETF at 13.187 billion yuan [2] - Ten additional products maintain scales between 1 billion and 8 billion yuan [2] Market Drivers - The expansion of innovative drug-themed ETFs is driven by multiple factors, including policy benefits, continuous institutional investment, improved liquidity, and the strengthening fundamentals of innovative drug companies [2] - The valuation of the innovative drug sector has recovered from previous lows, further stimulating investor interest [2] Industry Outlook - The Chinese pharmaceutical industry has completed a transition to new growth drivers, with innovative drugs opening new growth avenues for Chinese pharmaceutical companies [2] - The number and value of outbound licensing transactions for Chinese innovative drugs have reached new highs, indicating a positive outlook for the industry's prosperity [2] - The innovative drug sector is expected to enter a fundamental catalyst period, with advantages in patient resources, research and development costs, clinical efficiency, and policy support [2]

Group 1: Innovation Drug ETFs Performance - On October 31, innovation drug-themed ETFs collectively surged, with the top ten ETFs all being innovation drug-themed, each rising over 5% [1][2] - The top performers included the Science and Technology Innovation Drug ETFs from Huatai and Guotai, both exceeding 7% gains [2][3] - The Hong Kong Stock Connect Innovation Drug ETFs also showed strong performance, with gains over 5% [2][3] Group 2: Market Activity and Trends - On October 31, 11 ETFs had trading volumes exceeding 10 billion yuan, including several bond ETFs and cross-border ETFs like the Hong Kong Stock Connect Innovation Drug ETF [1][6] - On October 30, several industry ETFs, including securities, Hong Kong innovation drug, and medical ETFs, saw significant net inflows [8][9] - The previous trading day, broad-based ETFs experienced substantial net inflows, with those tracking the CSI 500 seeing over 1.1 billion yuan [8][9] Group 3: Decline in Communication Equipment ETFs - On October 31, communication equipment ETFs and communication ETFs led the decline, both dropping over 5% [4][5] - Specific ETFs such as the 5GETF and semiconductor equipment ETFs also experienced declines exceeding 4% [4][5] Group 4: Investment Opportunities in Innovation Drugs - The investment outlook for innovation drugs remains positive, with potential catalysts in the fourth quarter that could reactivate market sentiment [10] - The biotech sector in China is positioned as a key choice for multinational pharmaceutical companies due to its engineering talent and cost advantages [10] - The trend of domestic brands expanding internationally, particularly in sectors like automotive and innovation drugs, is expected to open up further market opportunities [10]

Group 1: Innovation Drug ETFs Performance - On October 31, innovation drug-themed ETFs collectively surged, with the top ten ETFs all being innovation drug-themed, each rising over 5% [1][2] - The top performers included the Science and Technology Innovation Drug ETFs from Huatai and Guotai, both exceeding 7% gains [2][3] - The Hong Kong Stock Connect Innovation Drug ETFs also showed strong performance, with gains over 5% [2][3] Group 2: Market Activity and Fund Flows - On October 31, 11 ETFs had trading volumes exceeding 10 billion yuan, including several bond ETFs and cross-border ETFs like the Hong Kong Stock Connect Innovation Drug ETF [1][6] - On October 30, several industry ETFs, including the Securities ETF and the Hong Kong Stock Connect Innovation Drug ETF, saw significant net inflows [8][9] - The Securities ETF led with a net inflow of 14.04 billion yuan on October 30 [9] Group 3: Communication Equipment ETFs Decline - On October 31, communication equipment ETFs and communication ETFs led the decline, both dropping over 5% [4][5] - Notable declines were observed in the 5GETF and semiconductor equipment ETFs, which fell over 4% [4][5] Group 4: Investment Opportunities in Innovation Drugs - The investment outlook for innovation drugs remains positive, with potential catalysts in the fourth quarter that could reactivate market sentiment [10] - The domestic biotech sector is seen as a key choice for multinational pharmaceutical companies due to its advantages in efficient research and development [10] - The trend of domestic brands expanding internationally, particularly in sectors like automotive and innovation drugs, is expected to open up further market opportunities [10]

Core Viewpoint - The innovative drug sector is experiencing fluctuations and adjustments, but the rise of AI drug development technologies is injecting new vitality into the industry, enhancing research efficiency and reducing costs, which is expected to bolster the sector's growth [1][4]. Group 1: Market Activity - Over 100 billion yuan has flowed into innovative drug-themed ETFs since August, with significant net subscriptions recorded, including 42.36 billion yuan for the Huatai-PineBridge Hong Kong Innovative Drug ETF and 40.93 billion yuan for the GF Hong Kong Innovative Drug ETF [2]. - On August 19, despite a drop of over 3% in several innovative drug ETFs, more than 30 billion yuan was still invested, indicating strong market interest [2]. - Several ETFs have reached record high shares since their inception, with the Huatai-PineBridge Hong Kong Innovative Drug ETF reaching 8.338 billion shares [2]. Group 2: Fund Management Actions - Multiple actively managed funds heavily invested in the innovative drug sector have restricted large subscriptions, such as the Changcheng Medical Industry Selected Mixed Fund limiting purchases to 1 million yuan [3]. - The Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund has also suspended subscriptions, reflecting a cautious approach amid market volatility [3]. Group 3: Institutional Insights - Fund managers believe that the innovative drug sector has significant long-term growth potential, driven by advancements in AI and ongoing policy support, which could position Chinese innovative drug companies more prominently in the global market [4][5]. - The profitability of leading innovative drug companies is improving, supported by a large domestic market and the potential for Chinese innovative drugs to capture 30% to 50% of the global market share, translating to a profit scale of 20 billion to 30 billion USD [5]. - The innovative drug sector is expected to continue its upward trajectory, with a focus on companies with strong fundamentals, while remaining vigilant about potential risks associated with market-driven stocks [5].

Market Performance - The Shanghai Composite Index reached a ten-year high of 3767.43 points on August 20, with the sci-tech chip sector experiencing significant gains, as multiple related ETFs rose over 4% [1] - On August 19, four ETFs saw net inflows exceeding 1 billion yuan, with the GF CSI Hong Kong Innovative Drug ETF receiving over 1.3 billion yuan [2] ETF Activity - The second batch of sci-tech bond ETFs was reported to the CSRC on August 20, with 14 fund companies submitting applications [3] - On August 20, several chip-themed ETFs performed strongly, with the Sci-Tech Chip Design ETF (588780) leading the market with a 5.57% increase [4][5] - The bond market saw active trading, with 10 ETFs exceeding 10 billion yuan in trading volume, seven of which were bond ETFs, including the Short-term Bond ETF (511360) with over 23 billion yuan in trading volume [6][8] Sector Insights - The innovative drug and sci-tech bond themed ETFs attracted significant capital inflows, indicating a positive trend in the innovative drug industry, which is expected to experience rapid revenue and profit growth over the next five years [9][10] - The light module sector is anticipated to maintain high prosperity due to the rapid development of the global AI industry, with increasing demand for computing power and related applications [11] New ETF Developments - The second batch of sci-tech bond ETFs will track various indices, including the CSI AAA Technology Innovation Corporate Bond Index and the SSE AAA Technology Innovation Corporate Bond Index [12]